JP4106263B2 - 炎症性の状態の治療のためのpparデルタ活性化因子の使用 - Google Patents

炎症性の状態の治療のためのpparデルタ活性化因子の使用 Download PDF

Info

Publication number
JP4106263B2
JP4106263B2 JP2002532258A JP2002532258A JP4106263B2 JP 4106263 B2 JP4106263 B2 JP 4106263B2 JP 2002532258 A JP2002532258 A JP 2002532258A JP 2002532258 A JP2002532258 A JP 2002532258A JP 4106263 B2 JP4106263 B2 JP 4106263B2
Authority
JP
Japan
Prior art keywords
methyl
acid
activator
compound
inos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002532258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004510750A (ja
JP2004510750A5 (cg-RX-API-DMAC7.html
Inventor
バカン,ケヴィン,ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2004510750A publication Critical patent/JP2004510750A/ja
Publication of JP2004510750A5 publication Critical patent/JP2004510750A5/ja
Application granted granted Critical
Publication of JP4106263B2 publication Critical patent/JP4106263B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
JP2002532258A 2000-10-05 2001-10-01 炎症性の状態の治療のためのpparデルタ活性化因子の使用 Expired - Fee Related JP4106263B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024361.8A GB0024361D0 (en) 2000-10-05 2000-10-05 Medicaments
PCT/GB2001/004373 WO2002028434A2 (en) 2000-10-05 2001-10-01 Use of a ppar delta activator for treating inflammatory conditions

Publications (3)

Publication Number Publication Date
JP2004510750A JP2004510750A (ja) 2004-04-08
JP2004510750A5 JP2004510750A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4106263B2 true JP4106263B2 (ja) 2008-06-25

Family

ID=9900709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002532258A Expired - Fee Related JP4106263B2 (ja) 2000-10-05 2001-10-01 炎症性の状態の治療のためのpparデルタ活性化因子の使用

Country Status (9)

Country Link
US (1) US7084161B2 (cg-RX-API-DMAC7.html)
EP (1) EP1324774B1 (cg-RX-API-DMAC7.html)
JP (1) JP4106263B2 (cg-RX-API-DMAC7.html)
AT (1) ATE318615T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001292046A1 (cg-RX-API-DMAC7.html)
DE (1) DE60117584T2 (cg-RX-API-DMAC7.html)
ES (1) ES2259675T3 (cg-RX-API-DMAC7.html)
GB (1) GB0024361D0 (cg-RX-API-DMAC7.html)
WO (1) WO2002028434A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
JP2004537525A (ja) * 2001-06-11 2004-12-16 メルク エンド カムパニー インコーポレーテッド PPARδアゴニストの投与による炎症性疾患の治療法
IL160845A0 (en) 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
FR2836829B1 (fr) * 2002-03-11 2005-11-25 Bio Merieux Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
AU2005231358A1 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. Use of PPR delta agonists for treating demyelinating diseases
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
DE602005020313D1 (de) 2004-08-12 2010-05-12 Amgen Inc Bisaryl-sulfonamide
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
BRPI0811612A2 (pt) * 2007-05-21 2014-11-11 Senju Pharma Co Composições farmacêuticas que contêm agonista ppardelta
US20110092517A1 (en) * 2009-08-14 2011-04-21 Cerenis Therapeutics S.A. & Nippon Chemiphar Co., Ltd. Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases
KR102038866B1 (ko) * 2012-12-24 2019-10-31 서울대학교산학협력단 PPARδ 활성물질의 항생제, 화상 및 창상 치료제, 당뇨성 족부궤양 치료제로서의 용도
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2004510750A (ja) 2004-04-08
DE60117584T2 (de) 2006-12-21
EP1324774B1 (en) 2006-03-01
EP1324774A2 (en) 2003-07-09
GB0024361D0 (en) 2000-11-22
AU2001292046A1 (en) 2002-04-15
ATE318615T1 (de) 2006-03-15
WO2002028434A3 (en) 2002-08-15
ES2259675T3 (es) 2006-10-16
DE60117584D1 (de) 2006-04-27
US7084161B2 (en) 2006-08-01
US20050131035A1 (en) 2005-06-16
WO2002028434A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
EP2776425B1 (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
JP2004510750A (ja) 炎症性の状態の治療のためのpparデルタ活性化因子の使用
US8975235B2 (en) Lysophosphatidic acid receptor antagonists
JP2022521824A (ja) アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用
TWI401082B (zh) 作為溶血磷脂酸受體拮抗劑之化合物
US8242145B2 (en) Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
AU2012333988A1 (en) New cyclohexylamine derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonist activities
US20140200215A1 (en) Lysophosphatidic acid receptor antagonists
JP6928986B2 (ja) キナーゼ活性を阻害するためのインダゾール系化合物、その組成物および使用
JP2003525217A (ja) 肥満治療用薬剤
JP2011513242A (ja) プロスタグランジンd2受容体アンタゴニスト
JP2006517564A (ja) Nurr−1アクチベーターとして有用な複素環化合物
US8030324B2 (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
CN102007098B (zh) 治疗性的取代的环戊烷
JP2004510749A (ja) No阻害またはtnf阻害に関連した疾病の治療におけるpparデルタ活性化因子の使用
JP2019147807A (ja) 肝臓x受容体(lxr)のモジュレーター
JP2002529458A (ja) PPAR−γリガンド
JP7107963B2 (ja) 置換されたn-アリールエチル-2-アリールキノリン-4-カルボキサミド類及びそれの使用
TWI644913B (zh) Bace1抑制劑
AU2006263884A1 (en) Quinoline derivatives as antibacterial agents
NZ624784B2 (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
HK1223015B (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
JPWO1999021844A1 (ja) 抗リウマチ剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080331

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110404

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees